Stefaan Van Gool MD. PhD.
Medizinischer Leiter der Translationalen Onkologie am IOZK
Medizinischer Leiter der Translationalen Onkologie am IOZK
Stefan Van Gool MD. PhD., ist Spezialist in pädiatrischer Hämato-Onkologie mit Schwerpunkt auf Hirntumore. Von 2001 bis 2004 war er Leiter der klinischen Forschung am Fonds für Wissenschaftlicher Forschung Flandern. Zwischen 2006 und 2016 war er Professor an der Medizinischen Fakultät der Katholischen Universität Leuven. 2012 bis 2015 war er Leiter des Labors für Pädiatrische Immunologie. Er ist Autor von fast 200 wissenschaftlichen Beiträgen in internationalen wissenschaftlichen Zeitschriften.
Als Anerkennung seiner wissenschaftlichen Leistungen, erhielt er folgende Auszeichnungen:
1995 Schweißguth Preis der International Society of Pediatric Oncology
1996 Nycomed Preis der International Society of Paediatric Oncology
1998 Preis für die Krebsforschung der Rik en Nel Wouters Foundation (mit Ludwig Van den Hove)
Zwischen 2005 und 2009 war er Koordinator der Europäischen Expertengruppe für High Grade Glioma
Seit 2008 ist er Mitglied des Hohen Gesundheitsrats in Belgien
Von 2014 bis 2017 war er Mitvorsitzender der Arbeitsgruppe für Hirntumore der European Society for Paediatric Oncology
Am IOZK ist er medizinischer Leiter und verantwortlich für die Planung und Durchführung der IOZK Immuntherapie. In der Arzneimittelherstellung ist er Sachkundige Person (GMP)
„Da jeder Tumor anders ist, erzielt man die besten Ergebnisse, wenn man mit patienteneigenen dendritischen Zellen gegen den einzigartigen Satz von Tumorzellen vorgeht“
Stefaan Van Gool MD. PhD.
The Complexity of Malignant Glioma Treatment
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Stefaan van Gool ist Herausgeber einer Sonderausgabe im Journal of Molecular Sciences
Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
Posterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
Impaired DNA repair in mouse monocytes compared to macrophages and precursors
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
IOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Symposium & Fortbildung am IOZK: Immuntherapie in der Neuroonkologie, Fr. 06.09.2019
Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy
Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group
IOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“
IOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin
IOZK Vortrag über die Effekte der multimodalen Immuntherapie bei einem Ponsgliom mit Hilfe der Analysemethode Flüssigbiopsie.
IOZK Vortrag von Stefaan Van Gool: IOZK Immuntherapie bei DIPG Ponsgliom, Konferenz der Society for Neuro-Oncology, San Francisco
Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival
Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade
Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy
IOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe
Artikel über Stefaan Van Gool als Kinderneuroonkologe in der Washington Post
Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease
Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group
Veröffentlichung von Stefaan Van Gool MD. PhD.: Electroporation of Dendritic Cells with WT1, Survivin, and TriMix
IOZK Beitrag in der Fachzeitschrift für Orthomolekulare Medizin, Sonderheft: Onkologie
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines
Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
Stefaan Van Gool wechselt von der Universität Leuven zum IOZK
Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
Brain Tumor Immunotherapy: What have We Learned so Far?
Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?
Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells
Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
Myeloid-derived suppressor cells in glioma
Dendritic cell-based immunotherapy in ovarian cancer
Immunotherapy for high-grade glioma: how to go beyond Phase I/II clinical trials
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination
Dendritic cell therapy of high-grade gliomas
Vaccine therapy in patients with renal cell carcinoma
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells
Dendritic cell vaccination in patients with malignant gliomas: current status and future directions
Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report